Gabe Ortiz, MD, PhD

Associate Professor

Gabriel Ortiz, MD, PhD, is an Assistant Clinical Professor at UCSF and a hospitalist at Zuckerberg San Francisco General. As the Medical Director of the Medical-Surgical Care Areas, he is focused on quality improvement work to enhance the care delivered to the vulnerable communities served by ZSFG. He is deeply engaged in applying Toyota's LEAN production and LEAN daily management systems as tools for achieving healthcare systems transformation (see links below for more information). Dr. Ortiz is also engaged in the implementation of Epic, the new enterprise EHR planned for ZSFG.
2018 - Diversity, Equity, and Inclusion Champion Training, University of California
Fellowship, 2012 - Infectious Diseases, UCSF
Chief Residency, 2008 - Internal Medicine, UCSF
Residency, 2007 - Internal Medicine, UCSF
MD, PhD, 2004 - Medicine and Human Immunology, Tri-Institutional MD, PhD Program
MS, BS, 1996 - Molecular Biophysics and Biochemistry, Yale Univeristy
  1. Acute Care for Patients Who Are Incarcerated: A Review.
  2. By the Light of Day: Quality, Safety, and Education During the Overnight Admission Handoff.
  3. Acute Clinical Care for Transgender Patients: A Review.
  4. Unusual Radiographic Presentation of Pneumocystis Pneumonia in a Patient with AIDS.
  5. Clearing the air: inpatient providers' knowledge, perspectives, and experience with electronic cigarettes.
  6. Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease.
  7. Morphine produces immunosuppressive effects in nonhuman primates at the proteomic and cellular levels.
  8. Detection of T lymphocytes specific for human endogenous retrovirus K (HERV-K) in patients with seminoma.
  9. Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3.
  10. Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection.
  11. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene.
  12. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study.
  13. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions.
  14. Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection.
  15. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.
  16. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.
  17. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection.
  18. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption.
  19. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy.
  20. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.
  21. “Acinetobacter in military personnel.” Case vignette as part of